Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.

Journal for Immunotherapy of Cancer
Ahmad TarhiniJohn M Kirkwood

Abstract

The impact of immune-related adverse events (irAEs) occurring from adjuvant use of immunotherapy and of their management on relapse-free survival (RFS) and overall survival (OS) outcomes is currently not well understood. E1609 enrolled 1673 patients with resected high-risk melanoma and evaluated adjuvant ipilimumab 3 mg/kg (ipi3) and 10 mg/kg (ipi10) versus interferon-α. We investigated the association of irAEs and of use of immunosuppressants with RFS and OS for patients treated with ipilimumab (n=1034). Occurrence of grades 1-2 irAEs was associated with RFS (5 years: 52% (95% CI 47% to 56%) vs 41% (95% CI 31% to 50%) with no AE; p=0.006) and a trend toward improved OS (5 years: 75% (95% CI 71% to 79%) compared with 67% (95% CI 56% to 75%) with no AE; p=0.064). Among specific irAEs, grades 1-2 rash was most significantly associated with RFS (p=0.002) and OS (p=0.003). In multivariate models adjusting for prognostic factors, the most significant associations were seen for grades 1-2 rash with RFS (p<0.001, HR=0.70) and OS (p=0.01, HR=0.71) and for grades 1-2 endocrine+rash with RFS (p<0.001, HR=0.66) and OS (p=0.008, HR=0.7). Overall, grades 1-2 irAEs had the best prognosis in terms of RFS and OS and those with grades 3-4 had l...Continue Reading

References

Nov 1, 1983·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J R AndersonR D Gelber
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A FranzkeJ Atzpodien
Feb 17, 2006·The New England Journal of Medicine·Helen GogasJohn M Kirkwood
May 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kimberly E BeckJames C Yang
Nov 6, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stephanie G DowneySteven A Rosenberg
Mar 23, 2010·Cell·Lauren A ZenewiczJudy H Cho
Dec 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ahmad A TarhiniJohn M Kirkwood
Apr 29, 2014·Gastroenterology·Ynto S de BoerUNKNOWN Study of Health in Pomerania
Nov 5, 2014·JAMA : the Journal of the American Medical Association·F Stephen HodiJohn M Kirkwood
Jul 30, 2015·JAMA Dermatology·Martina SanlorenzoSusana Ortiz-Urda
May 5, 2016·Nature Reviews. Clinical Oncology·Celine BoutrosCaroline Robert
Mar 11, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chen WangEllen L Goode
Sep 12, 2017·The New England Journal of Medicine·Jedd D WolchokJames Larkin
Aug 21, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathryn C ArbourMatthew D Hellmann
Jun 18, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Biagio RicciutiMark M Awad
Dec 28, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ahmad A TarhiniJohn M Kirkwood

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.